Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.15M
ATNM Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Actinium Pharmaceuticals, Inc.AMEX: ATNM
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow growth accelerates
Q2 FY2026 free cash flow of $5.66M (cash outflow) rose 4.9% year over year, ahead of the -24.3% change in trailing-twelve-month free cash flow. Sequentially, it fell 3.7% from the prior quarter.
Context
- Free cash flow amounted to 27426.7% of revenue in FY2025.
- Free cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +4.9% holds above the trailing-twelve-month pace of -24.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (24.68M) USD
- Year-over-year change
- +25.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24.68M) | +25.4% |
| FY2024 | 2024-12-31 | (33.08M) | +30.3% |
| FY2023 | 2023-12-31 | (47.49M) | -673.7% |
| FY2022 | 2022-12-31 | 8.28M | +139.4% |
| FY2021 | 2021-12-31 | (21M) | — |
Free Cash Flow vs competitors
How ATNM compares with its peers on the latest reported figures
- ATNM's LTM Jun 2026 free cash flow of $23.25M is the smallest of the 5 companies compared; the peer median is $54.08M.
- Its year-over-year change of -24.3% is the 4th highest of 5, against a peer median of +6.4%.
- Free cash flow amounts to 66.2% of revenue for ATNM, versus a peer median of 107.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.39B | +12754.9% | +925.8% | — | |
| LTM Mar 2026 | $57.37M | -372.6% | -58.6% | 107.3% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $50.79M | -2.8% | +22.7% | — |
| LTM Mar 2026 | $26.53M | +15.6% | +1039.6% | — | |
| LTM Jun 2026 | $23.25M | -24.3% | — | 66.2% | |
| Peer median (excluding ATNM) | $54.08M | +6.4% | +474.2% | 107.3% | |
Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| Deferred Income Tax | (1.55M) | 402K | 0 | 0 | 0 |
| Stock-Based Compensation | 1.69M | 2.8M | 3.84M | 5.29M | 9.19M |
| Change in Working Capital | 1.69M | 38.17M | (3.15M) | (932K) | (704K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 4.6M | (2.18M) | (387K) | (346K) |
| Other Working Capital | 495K | 33.57M | (972K) | (545K) | (358K) |
| Other Non-Cash Items | 1.55M | (402K) | 0 | 0 | 0 |
| Operating Cash Flow | (20.87M) | 8.64M | (47.34M) | (33.07M) | (24.58M) |
| Capital Expenditures | (133K) | (366K) | (153K) | (11K) | (104K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (133K) | (366K) | (153K) | (11K) | (104K) |
| Debt Repayment | (85K) | (49K) | (4K) | (9K) | (10K) |
| Common Stock Issued | 35.3M | 23.16M | 14.87M | 29.26M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (207K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6K | 0 | 0 | 75K | 0 |
| Financing Cash Flow | 35.22M | 23.11M | 14.87M | 29.32M | (217K) |
| Effect of Forex Changes | 0 | 0 | (11K) | 0 | 6K |
| Net Change in Cash | 14.22M | 31.39M | (32.63M) | (3.76M) | (24.9M) |
| Free Cash Flow | (21M) | 8.28M | (47.49M) | (33.08M) | (24.68M) |
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.